@article {Cortezzo2021.10.08.21264249, author = {DonnaMaria E. Cortezzo and Leandra K. Tolusso and Daniel T. Swarr}, title = {Perinatal Outcomes of Fetuses and Infants Diagnosed with Trisomy 13 or Trisomy 18}, elocation-id = {2021.10.08.21264249}, year = {2021}, doi = {10.1101/2021.10.08.21264249}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives To identify factors associated with adverse prenatal, perinatal and postnatal outcomes, and determine the utilization medical care for fetuses \& infants with trisomy 13 (T13) and trisomy (T18).Study Design This population-based retrospective cohort study included all prenatal and postnatal diagnoses of T13 or T18 in the Greater Cincinnati area from 1/1/12-12/31/18. Overall survival, survival to hospital discharge, approach to medical management, and maternal, fetal and neonatal characteristics are analyzed.Results 124 pregnancies (125 fetuses) were identified, which resulted in 72 liveborn infants. Male fetal sex and hydrops were associated with a higher rate of spontaneous loss. The median length of survival was 7 days (95\% CI, 0-18 days) and 29 days (95\% CI, 2-115 days), for infants with T13 and T18, respectively. Of the 27 infants who were alive at 1 month of age, 14 (52\%) were alive at 1 year of age. Only the trisomy type, chosen goals of care (comfort care), and extremely low birthweight were associated with overall length of survival. A high degree of variability existed in the use of medical services, with 28\% of infants undergoing at least one surgical procedure and some children requiring repeated (up to 29) or prolonged hospitalization (\> 1 year).Conclusions Although many infants with T13 or T18 did not survive past the first week of life, up to 25\% of infants lived for more than one year. Length of survival for an individual infant cannot be easily predicted, and surviving infants have high health care utilization throughout their lifespan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDTS received funding from NIH R01HL156860 during the study period.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Cincinnati Childrens Hospital Institutional Review Board (IRB), as well as each IRB for all hospitals with obstetrics services across the Greater Cincinnati Region.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCHDCongenital Heart DiseaseELBWExtremely Low BirthweightELGANExtremely Low Gestational Age NeonateNICUNeonatal Intensive Care UnitT13Trisomy 13T18Trisomy 18VLGANVery Low Gestational Age Neonate}, URL = {https://www.medrxiv.org/content/early/2021/10/09/2021.10.08.21264249}, eprint = {https://www.medrxiv.org/content/early/2021/10/09/2021.10.08.21264249.full.pdf}, journal = {medRxiv} }